Digital depression therapy that puts your patient first
Using proven CBT techniques, deprexis® helps patients with depression make lasting progress.1,2
Help patients reclaim better days
deprexis® is one of the most researched digital therapies in the world, studied in 11 clinical trials with >2800 patients.1-11
Making progress personal
Over the course of 10 content modules, deprexis® learns from patient input to provide responses that are customized to their specific needs.1
The CBT standard
deprexis® digitally integrates CBT techniques to alleviate negative thought and behavior patterns that block the potential for progress.1,12
Fits into any treatment plan
Whether a patient is new to therapy or seeking additional treatment, deprexis® fits in seamlessly.1
Always available
deprexis® is accessible 24/7 on desktop and mobile, giving patients access where and when they need it most.2,13
Short TermIn a clinical study, people who added deprexis® to their care plan were 12x more likely to have an improvement in at least half of their symptoms compared with patients who did not add deprexis® to their care plan.2
In a clinical study, people who added deprexis® to their care plan were 12x more likely to have an improvement in at least half of their symptoms compared with patients who did not add deprexis® to their care plan.2
Long Term
In another clinical study, patients who added deprexis® to their care plan saw a reduction in their depression symptoms 6 months after the program ended.1
Access to deprexis®
deprexis® is available to patients through their insurance provider, employer benefits, or through self-payment. Enroll in our deprexis® Compass program to find out if your patient is covered.
There when you need us
Our team is always here to answer any questions regarding access to deprexis®, coverage information, or technical support.
- Reach us by email at deprexissupport@orexo.com
- Give us a call at 1-833-DEPREXIS Monday through Friday: 8 AM to
8 PM ET
deprexis is a web application indicated for the adjunctive treatment of chronic or recurrent depression or depressive disorders as a primary or secondary diagnosis (eg, as a comorbidity in multiple sclerosis or epilepsy) for patients 18 years of age or older who are experiencing
a depressive episode.
1. Meyer B, Berger T, Caspar F, Beevers CG, Andersson G, Weiss M. Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res. 2009;11(2):e15. doi:10.2196/jmir.1151. 2. Beevers CG, Pearson R, Hoffman JS, Foulser AA, Shumake J, Meyer B. Effectiveness of an internet intervention (deprexis) for depression in a United States adult sample: a parallel-group pragmatic randomized controlled trial. J Consult Clin Psychol. 2017;85(4):367-380. doi:10.1037/ccp0000171. 3. Meyer B, Bierbrodt J, Schröder J, et al. Effects of an internet intervention (deprexis) on severe depression symptoms: Randomized controlled trial. Internet Interventions. 2015;2(1):48-59. doi:10.1016/j.invent.2014.12.003. 4. Berger T, Hämmerli K, Gubser N, Andersson G, Caspar F. Internet-based treatment of depression: a randomized controlled trial comparing guided with unguided self-help. Cogn Behav Ther. 2011;40(4):251-266. doi:10.1080/16506073.2011.616531. 5. Moritz S, Schilling L, Hauschildt M, Schröder J, Treszl A. A randomized controlled trial of internet-based therapy in depression. Behav Res Ther. 2012;50(7-8):513-521. doi:10.1016/j.brat.2012.04.006. 6. Schröder J, Brückner K, Fischer A, et al. Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial. Epilepsia. 2014;55(12):2069-2076. doi:10.1111/epi.12833. 7. Fischer A, Schröder J, Vettorazzi E, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry. 2015;2(3):217-223. doi:10.1016/S2215-0366(14)00049-2. 8. Klein JP, Berger T, Schröder J, et al. Effects of a psychological internet intervention in the treatment of mild to moderate depressive symptoms: results of the EVIDENT study, a randomized controlled trial. Psychother Psychosom. 2016;85(4):218-228. doi:10.1159/000445355. 9. Berger T. Evaluating an e-mental health program ("deprexis") as adjunctive treatment tool in psychotherapy for depression: results of a pragmatic randomized controlled trial. J Affect Disord. 2017;227:455-462. 10. Zwerenz R, Becker J, Knickenberg RJ, et al. Online self-help as an add-on to inpatient psychotherapy: efficacy of a new blended treatment approach. Psychotherapy and Psychosomatics. 2017; 86(6):341-350. 11. Bücker L, Bierbrodt J, Hand I, Wittekind C, Moritz S. Effects of a depression-focused internet intervention in slot machine gamblers: a randomized controlled trial [published correction appears in PLoS One. Aug 23, 2018;13(8):e0203145]. PLoS One. 2018;13(6):e0198859. doi:10.1371/journal.pone.0198859. 12. American Psychological Association. What is cognitive behavioral therapy? Clinical practice guideline for the treatment of posttraumatic stress disorder. July 2017. Accessed June 9, 2020. https://www.apa.org/ptsd-guideline/patients-and-families/cognitive-behavioral.pdf. 13. Orexo acquires exclusive US rights to commercialize deprexis®, a world-leading digital therapy to help patients manage the symptoms of depression. News release. Orexo AB (publ.). May 11, 2020. Accessed October 30, 2020. https://orexo.com/media/regulatory-pressreleases?releaseId=9CC5F2D2BF210584.
deprexis® is not a healthcare provider and does not provide medical advice, diagnosis, or standalone treatment. If patients need immediate medical attention, they should contact their healthcare provider or go to the closest emergency room.